| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/30/2010 | CN101757103A Medicine composition for treating idiopathic thrombocytopenic purpura |
| 06/30/2010 | CN101757097A Preparation of walnut leaf extracts and application prospect thereof in field of memory improvement and antitumor |
| 06/30/2010 | CN101757072A Method for enriching and purifying rhizoma atractylodis volatile oil in rhizoma atractylodis |
| 06/30/2010 | CN101757057A Whiteflower leadword root chewable tablet |
| 06/30/2010 | CN101757056A Extract of yangtao actinidia root and preparation method and applications thereof |
| 06/30/2010 | CN101757049A Ginkgo leaf extractive and method for extracting total ginkgoic acid in preparation thereof |
| 06/30/2010 | CN101757047A Purification method of pseudolaric acid B |
| 06/30/2010 | CN101757039A Bionic enzymolysis products of geckos and application thereof |
| 06/30/2010 | CN101756997A Application of cucurbitacin glucoside in preparation of medicine for treating cancer |
| 06/30/2010 | CN101756996A Application of cucurbitacin glucoside in preparation of medicine for treating cancer |
| 06/30/2010 | CN101756992A High-activity anti-caner new medicament formalardeemin for inhibiting multi-drug resistance of tumor cells |
| 06/30/2010 | CN101756988A Compound matrine and diversine nano-emulsion preparation and preparation method thereof |
| 06/30/2010 | CN101756984A Application of pyrro-quinoline quinine in treating and preventing atherosclerosis |
| 06/30/2010 | CN101756957A Pharmaceutical composition containing artemisinin, artemisinin derivatives and histon deacetylase (HDAC) inhibitor and application thereof |
| 06/30/2010 | CN101756956A Use of catechin for preparing retrovirus integrase inhibitors |
| 06/30/2010 | CN101756921A Hydroxyurea tablet and preparation method thereof |
| 06/30/2010 | CN101756904A Preparation process for chitosan microsphere |
| 06/30/2010 | CN101756903A Preparation process of nanometer magnetic drug-carrying gene-carrying thermal controlled release liposome |
| 06/30/2010 | CN101756900A Elemene micro-emulsion |
| 06/30/2010 | CN101756891A Cladribine preparation administrated by injection and preparation method thereof |
| 06/30/2010 | CN101756888A Temperature-controlled sustained-release injection containing isoliquiritigenin and preparation method thereof |
| 06/30/2010 | CN101756887A Shell-crosslinked polymeric micelles by using metal nanoparticles as crosslinking agent |
| 06/30/2010 | CN101317852B Powder injection of compound glycyrrhizic acid glycosides and preparation method thereof |
| 06/30/2010 | CN101292987B Pharmaceutical combination |
| 06/30/2010 | CN101283999B Medicinal composition mainly for curing cardiovascular and cerebrovascular diseases and preparation method thereof |
| 06/30/2010 | CN101234122B New purpose of polylysine |
| 06/30/2010 | CN101199861B DNA vaccine for resisting liver cancer |
| 06/30/2010 | CN101168064B Recombination human pancreatic cancer mucus protein core peptide DNA vaccine |
| 06/30/2010 | CN101095669B Osthole phospholipid complexes and method for preparing the same and application thereof |
| 06/30/2010 | CN101084874B Method for preparing water soluble hypocrellin silica nanometer particle and its application in preparing venous injection |
| 06/29/2010 | US7745639 Dihydropyrazoles; anticarcinogenic agents can be synergistically combined with one or more active ingredients; side effect reduction |
| 06/29/2010 | US7745638 Anticancer agents; such as 4-acetylamino-1H-pyrazole-3-carboxylic acid (4-fluoro-phenyl)-amide |
| 06/29/2010 | US7745622 Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate |
| 06/29/2010 | US7745619 alkaloids; anticarcinogenic, antiproliferative agent; inhibitor of cellular mitosis and cell proliferation; binding to tubulin leads to cell cycle arrest in M phase and subsequently to apoptosis; antiallergen, antiinflammatory, antidiabetic, autoimmune diseases; asthma, arthritis, Alzheimer' disease |
| 06/29/2010 | US7745585 humanized, chimeric, genetic engineered, monoclonal or polyclonal antibody, or fragment, useful in the therapy of cancer, fibrosis and chronic obstructive pulmonary disease |
| 06/29/2010 | US7745581 T-bet compositions and methods of use thereof |
| 06/29/2010 | US7745572 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 06/29/2010 | US7745485 Inhibiting metastasis of cancer cells by administering a phosphatidyl inositol 3-kinase inhibitor such as Wortmannin or LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) |
| 06/29/2010 | US7745481 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia |
| 06/29/2010 | US7745473 Indole derivative for alkylating specific base sequence of DNA and alkylating agent and drug containing the derivative |
| 06/29/2010 | US7745472 Dimethylsulfamic Acid 2-bromo-4-{[(4-cyano-phenyl)-[1,2,4]triazol-4-ylamino]methyl}phenyl Ester, used as effective sulfatase and/or aromatase inhibitors, and as modulators of cell cycling and modulators of apoptosis; therapy of breast, prostate, ovarian or endometrial cancer |
| 06/29/2010 | US7745465 Antiischemic agents; antiinflammatory agents; antiallergens; autoimmune disease |
| 06/29/2010 | US7745450 5-[1-(hydroxymethyl)propyl]amino-7-benzylamino-3-isopropyl(methyl, ethyl)pyrazolo[4,3-d]pyrimidine for inhibiting cell proliferation, cancer, or psoriasis, rheumatoid arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, and neurodegerative diseases |
| 06/29/2010 | US7745448 Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate |
| 06/29/2010 | US7745446 such as 4-Aminomethyl-N-[4-(5-biphenyl-4-yl-pyrazolo[1,5-c]pyrimidin-7-ylamino)-phenyl]-benzamide, useful in the therapy of (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis |
| 06/29/2010 | US7745424 Osteoporosis, bone cancer; antiarthritic agents;paget's disease; antiinflammatory agents |
| 06/29/2010 | US7745420 stability, high effectiveness and low toxicity; for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis |
| 06/29/2010 | US7745418 Compositions and methods for inhibiting viral replication |
| 06/29/2010 | US7745395 Recombinant protease comprising prostate-specific protease cleavage site and deficient in furin cleavage site for use as therapeutic agent in treatment of cell proliferative disorders; antitumor agents |
| 06/29/2010 | US7745388 Peptide for use in the treatment of cell damage caused by ischemia |
| 06/29/2010 | US7745212 Melanoma antigens and their use in diagnostic and therapeutic methods |
| 06/29/2010 | US7745198 producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation using genus Mortierella, the genus Streptomyces or the family Micromonosporaceae |
| 06/29/2010 | US7745165 Calibration of colorectal cancer; gene expression profile; administering to human an antibody which binds to protein markers |
| 06/29/2010 | US7745154 Preventives/remedies for myeloma tumor and method of diagnosing the same |
| 06/29/2010 | US7745139 for eliminating specifically binding, cell-physiologically active, pathological antibodies in preeclampsia and malign hypertension |
| 06/29/2010 | US7745114 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 06/29/2010 | US7745109 Regulation of cell growth by MUC1 |
| 06/29/2010 | US7744921 Liposome loading with metal ions |
| 06/29/2010 | US7744909 Dispersions for the formulation of slightly or poorly soluble agents |
| 06/29/2010 | US7744899 Preferentially kills tumor cells and not healthy cells; expresses only one gamma 134.5 gene copy and that comprises an expressibletumor-growth-inhibiting cytokine-encoding DNA; anticarcinogenic agents; antitumor agents; nervous system disorders; immunotherapy;tissue-targeted therapy |
| 06/29/2010 | US7744896 therapeutic vaccine anti-HIV, anti-AIDS and against tumors and syndromes associated with HIV infection |
| 06/29/2010 | US7744888 Controlling immunology response; autoimmune disease, antiallergens |
| 06/29/2010 | US7744881 for cancer treatment by inducing apoptosis; monoclonal antibodies; drug conjugated with polyoxyethylene glycol or enzyme or radioisotope, fluorescent compound or chemiluminescent compound; genetic engineering; biodrugs; anticarcinogenic agents |
| 06/29/2010 | US7744880 cell proliferation-inhibiting activity by ADCC (antibody-dependent cell-mediated cytotoxicity) activity and CDC (complement-dependent cytotoxicity); hepatic cancer |
| 06/29/2010 | US7744878 Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof |
| 06/29/2010 | US7744871 comprising an antibody against an EGF receptor and a vaccine which induces antibodies against EGF or TGF alpha; based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) |
| 06/29/2010 | CA2557856C 3-'4-heterocyclyl-1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases |
| 06/29/2010 | CA2542007C Protein tyrosine kinase inhibitors |
| 06/29/2010 | CA2455628C Neuroprotective drug comprising flibanserin |
| 06/29/2010 | CA2424596C Oral self-emulsifying formulations of pyranone protease inhibitors |
| 06/29/2010 | CA2417942C 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
| 06/29/2010 | CA2415280C Use of halogenated xanthenes as anti-cancer and anti-bacterial agents |
| 06/29/2010 | CA2409090C Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 06/29/2010 | CA2404737C Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug |
| 06/29/2010 | CA2382389C Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| 06/29/2010 | CA2379734C Treatment of cancers |
| 06/29/2010 | CA2373530C Taxane derivatives and processes for the preparation thereof |
| 06/29/2010 | CA2366765C Vacuolar-type (h+) -atpase-inhibiting compounds, compositions, and uses thereof |
| 06/29/2010 | CA2187346C Receptor modulating agents and methods relating thereto |
| 06/29/2010 | CA2168409C G cap-stabilized oligonucleotides |
| 06/29/2010 | CA2134030C Soluble interferon .alpha.-receptor, its preparation and use |
| 06/24/2010 | WO2010071885A1 Pyrrolotriazines as alk and jak2 inhibitors |
| 06/24/2010 | WO2010071852A2 Oligonucleotide micelles |
| 06/24/2010 | WO2010071837A1 Pyrazine derivatives useful as inhibitors of atr kinase |
| 06/24/2010 | WO2010071783A1 Thiazoles as cannabinoid receptor ligands |
| 06/24/2010 | WO2010071308A1 Composition for improving radiotherapy for cancer |
| 06/24/2010 | WO2010071230A1 Photodynamic therapeutic agent showing accumulation of cell-specific functions |
| 06/24/2010 | WO2010070877A1 Elovl7 epitope peptides and vaccines containing the same |
| 06/24/2010 | WO2010070379A1 Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer |
| 06/24/2010 | WO2010070365A1 1,3-heterocycles condensed with monoterpene skeleton, their use and pharmaceutical compositions comprising such compounds |
| 06/24/2010 | WO2010070134A1 Monoclonal antibodies directed against lg4-5 domain of alpha3 chain of human laminin-5 |
| 06/24/2010 | WO2010070117A1 Treatment method by the administration of anti-her2 targeted active compounds to patients with early breast cancer and her2-negative primary tumor |
| 06/24/2010 | WO2010070076A1 Alkanoic acid derivatives and their therapeutic use as hdac inhibitors |
| 06/24/2010 | WO2010070060A1 Bicyclic pyrazoles as protein kinase inhibitors |
| 06/24/2010 | WO2010069966A1 Substituted indazole derivatives active as kinase inhibitors |
| 06/24/2010 | WO2010069941A1 Conjugates comprising nanoparticles coated with platinum containing compounds |
| 06/24/2010 | WO2010069929A1 Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma. |
| 06/24/2010 | WO2010069850A1 Macrolactone derivatives, method for the production thereof and use thereof for the treatment of cancer |
| 06/24/2010 | WO2010069765A1 ANTI-cMET ANTIBODY |
| 06/24/2010 | WO2010069532A1 Antibodies against human angiopoietin 2 |